Global Live Attenuated Influenza Vaccine (LAIV) Market Research Report 2024, Forecast to 2032
Report Overview
A Live Attenuated Influenza Vaccine (LAIV), also known as the 'nasal spray' or 'intranasal' flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.
The global Live Attenuated Influenza Vaccine (LAIV) market size was estimated at USD 7740.50 million in 2023 and is projected to reach USD 13414.31 million by 2032, exhibiting a CAGR of 6.30% during the forecast period.
North America Live Attenuated Influenza Vaccine (LAIV) market size was estimated at USD 2240.67 million in 2023, at a CAGR of 5.40% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global Live Attenuated Influenza Vaccine (LAIV) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Live Attenuated Influenza Vaccine (LAIV) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Live Attenuated Influenza Vaccine (LAIV) market in any manner.
Global Live Attenuated Influenza Vaccine (LAIV) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology
Market Segmentation (by Type)
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine
Market Segmentation (by Application)
Hospital
Clinic
Public Health Agency
Other
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Live Attenuated Influenza Vaccine (LAIV) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Live Attenuated Influenza Vaccine (LAIV), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
A Live Attenuated Influenza Vaccine (LAIV), also known as the 'nasal spray' or 'intranasal' flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.
The global Live Attenuated Influenza Vaccine (LAIV) market size was estimated at USD 7740.50 million in 2023 and is projected to reach USD 13414.31 million by 2032, exhibiting a CAGR of 6.30% during the forecast period.
North America Live Attenuated Influenza Vaccine (LAIV) market size was estimated at USD 2240.67 million in 2023, at a CAGR of 5.40% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global Live Attenuated Influenza Vaccine (LAIV) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Live Attenuated Influenza Vaccine (LAIV) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Live Attenuated Influenza Vaccine (LAIV) market in any manner.
Global Live Attenuated Influenza Vaccine (LAIV) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology
Market Segmentation (by Type)
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine
Market Segmentation (by Application)
Hospital
Clinic
Public Health Agency
Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Live Attenuated Influenza Vaccine (LAIV) Market
- Overview of the regional outlook of the Live Attenuated Influenza Vaccine (LAIV) Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Live Attenuated Influenza Vaccine (LAIV) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Live Attenuated Influenza Vaccine (LAIV), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Live Attenuated Influenza Vaccine (LAIV)
1.2 Key Market Segments
1.2.1 Live Attenuated Influenza Vaccine (LAIV) Segment by Type
1.2.2 Live Attenuated Influenza Vaccine (LAIV) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET COMPETITIVE LANDSCAPE
3.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Manufacturers (2019-2024)
3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Manufacturers (2019-2024)
3.3 Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Live Attenuated Influenza Vaccine (LAIV) Sales Sites, Area Served, Product Type
3.6 Live Attenuated Influenza Vaccine (LAIV) Market Competitive Situation and Trends
3.6.1 Live Attenuated Influenza Vaccine (LAIV) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Live Attenuated Influenza Vaccine (LAIV) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) INDUSTRY CHAIN ANALYSIS
4.1 Live Attenuated Influenza Vaccine (LAIV) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2019-2024)
6.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Market Share by Type (2019-2024)
6.4 Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2019-2024)
7 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Sales by Application (2019-2024)
7.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) by Application (2019-2024)
7.4 Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2019-2024)
8 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET CONSUMPTION BY REGION
8.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region
8.2 North America
8.2.1 North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET PRODUCTION BY REGION
9.1 Global Production of Live Attenuated Influenza Vaccine (LAIV) by Region (2019-2024)
9.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2019-2024)
9.3 Global Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Live Attenuated Influenza Vaccine (LAIV) Production
9.4.1 North America Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2019-2024)
9.4.2 North America Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Live Attenuated Influenza Vaccine (LAIV) Production
9.5.1 Europe Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2019-2024)
9.5.2 Europe Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Live Attenuated Influenza Vaccine (LAIV) Production (2019-2024)
9.6.1 Japan Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2019-2024)
9.6.2 Japan Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Live Attenuated Influenza Vaccine (LAIV) Production (2019-2024)
9.7.1 China Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2019-2024)
9.7.2 China Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 Sanofi Pasteur
10.1.1 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.1.2 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.1.4 Sanofi Pasteur Business Overview
10.1.5 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis
10.1.6 Sanofi Pasteur Recent Developments
10.2 AstraZeneca
10.2.1 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.2.2 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.2.4 AstraZeneca Business Overview
10.2.5 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis
10.2.6 AstraZeneca Recent Developments
10.3 CSL
10.3.1 CSL Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.3.2 CSL Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.3.4 CSL Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis
10.3.5 CSL Business Overview
10.3.6 CSL Recent Developments
10.4 Abbott
10.4.1 Abbott Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.4.2 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.4.4 Abbott Business Overview
10.4.5 Abbott Recent Developments
10.5 GlaxoSmithKline
10.5.1 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.5.2 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.5.4 GlaxoSmithKline Business Overview
10.5.5 GlaxoSmithKline Recent Developments
10.6 Serum Institute
10.6.1 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.6.2 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.6.4 Serum Institute Business Overview
10.6.5 Serum Institute Recent Developments
10.7 Fluenz Tetra
10.7.1 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.7.2 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.7.4 Fluenz Tetra Business Overview
10.7.5 Fluenz Tetra Recent Developments
10.8 Cytiva
10.8.1 Cytiva Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.8.2 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.8.4 Cytiva Business Overview
10.8.5 Cytiva Recent Developments
10.9 BioDiem
10.9.1 BioDiem Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.9.2 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.9.4 BioDiem Business Overview
10.9.5 BioDiem Recent Developments
10.10 FluMist
10.10.1 FluMist Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.10.2 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.10.4 FluMist Business Overview
10.10.5 FluMist Recent Developments
10.11 GSK
10.11.1 GSK Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.11.4 GSK Business Overview
10.11.5 GSK Recent Developments
10.12 ChangChun High and New Technology
10.12.1 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.12.2 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.12.3 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.12.4 ChangChun High and New Technology Business Overview
10.12.5 ChangChun High and New Technology Recent Developments
10.13 BCHT Biotechnology
10.13.1 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.13.4 BCHT Biotechnology Business Overview
10.13.5 BCHT Biotechnology Recent Developments
11 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET FORECAST BY REGION
11.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast
11.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country
11.2.3 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region
11.2.4 South America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Live Attenuated Influenza Vaccine (LAIV) by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Live Attenuated Influenza Vaccine (LAIV) by Type (2025-2032)
12.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Live Attenuated Influenza Vaccine (LAIV) by Type (2025-2032)
12.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Application (2025-2032)
12.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) Forecast by Application
12.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Live Attenuated Influenza Vaccine (LAIV)
1.2 Key Market Segments
1.2.1 Live Attenuated Influenza Vaccine (LAIV) Segment by Type
1.2.2 Live Attenuated Influenza Vaccine (LAIV) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET COMPETITIVE LANDSCAPE
3.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Manufacturers (2019-2024)
3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Manufacturers (2019-2024)
3.3 Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Live Attenuated Influenza Vaccine (LAIV) Sales Sites, Area Served, Product Type
3.6 Live Attenuated Influenza Vaccine (LAIV) Market Competitive Situation and Trends
3.6.1 Live Attenuated Influenza Vaccine (LAIV) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Live Attenuated Influenza Vaccine (LAIV) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) INDUSTRY CHAIN ANALYSIS
4.1 Live Attenuated Influenza Vaccine (LAIV) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2019-2024)
6.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Market Share by Type (2019-2024)
6.4 Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2019-2024)
7 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Sales by Application (2019-2024)
7.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) by Application (2019-2024)
7.4 Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2019-2024)
8 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET CONSUMPTION BY REGION
8.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region
8.2 North America
8.2.1 North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET PRODUCTION BY REGION
9.1 Global Production of Live Attenuated Influenza Vaccine (LAIV) by Region (2019-2024)
9.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2019-2024)
9.3 Global Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Live Attenuated Influenza Vaccine (LAIV) Production
9.4.1 North America Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2019-2024)
9.4.2 North America Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Live Attenuated Influenza Vaccine (LAIV) Production
9.5.1 Europe Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2019-2024)
9.5.2 Europe Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Live Attenuated Influenza Vaccine (LAIV) Production (2019-2024)
9.6.1 Japan Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2019-2024)
9.6.2 Japan Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Live Attenuated Influenza Vaccine (LAIV) Production (2019-2024)
9.7.1 China Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2019-2024)
9.7.2 China Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 Sanofi Pasteur
10.1.1 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.1.2 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.1.4 Sanofi Pasteur Business Overview
10.1.5 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis
10.1.6 Sanofi Pasteur Recent Developments
10.2 AstraZeneca
10.2.1 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.2.2 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.2.4 AstraZeneca Business Overview
10.2.5 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis
10.2.6 AstraZeneca Recent Developments
10.3 CSL
10.3.1 CSL Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.3.2 CSL Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.3.4 CSL Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis
10.3.5 CSL Business Overview
10.3.6 CSL Recent Developments
10.4 Abbott
10.4.1 Abbott Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.4.2 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.4.4 Abbott Business Overview
10.4.5 Abbott Recent Developments
10.5 GlaxoSmithKline
10.5.1 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.5.2 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.5.4 GlaxoSmithKline Business Overview
10.5.5 GlaxoSmithKline Recent Developments
10.6 Serum Institute
10.6.1 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.6.2 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.6.4 Serum Institute Business Overview
10.6.5 Serum Institute Recent Developments
10.7 Fluenz Tetra
10.7.1 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.7.2 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.7.4 Fluenz Tetra Business Overview
10.7.5 Fluenz Tetra Recent Developments
10.8 Cytiva
10.8.1 Cytiva Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.8.2 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.8.4 Cytiva Business Overview
10.8.5 Cytiva Recent Developments
10.9 BioDiem
10.9.1 BioDiem Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.9.2 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.9.4 BioDiem Business Overview
10.9.5 BioDiem Recent Developments
10.10 FluMist
10.10.1 FluMist Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.10.2 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.10.4 FluMist Business Overview
10.10.5 FluMist Recent Developments
10.11 GSK
10.11.1 GSK Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.11.4 GSK Business Overview
10.11.5 GSK Recent Developments
10.12 ChangChun High and New Technology
10.12.1 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.12.2 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.12.3 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.12.4 ChangChun High and New Technology Business Overview
10.12.5 ChangChun High and New Technology Recent Developments
10.13 BCHT Biotechnology
10.13.1 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Basic Information
10.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Overview
10.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
10.13.4 BCHT Biotechnology Business Overview
10.13.5 BCHT Biotechnology Recent Developments
11 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET FORECAST BY REGION
11.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast
11.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country
11.2.3 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region
11.2.4 South America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Live Attenuated Influenza Vaccine (LAIV) by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Live Attenuated Influenza Vaccine (LAIV) by Type (2025-2032)
12.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Live Attenuated Influenza Vaccine (LAIV) by Type (2025-2032)
12.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Application (2025-2032)
12.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) Forecast by Application
12.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Live Attenuated Influenza Vaccine (LAIV) Market Size Comparison by Region (M USD)
Table 5. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Manufacturers (2019-2024)
Table 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Influenza Vaccine (LAIV) as of 2022)
Table 10. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (USD/MT) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Live Attenuated Influenza Vaccine (LAIV) Sales Sites and Area Served
Table 12. Manufacturers Live Attenuated Influenza Vaccine (LAIV) Product Type
Table 13. Global Live Attenuated Influenza Vaccine (LAIV) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Live Attenuated Influenza Vaccine (LAIV)
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Live Attenuated Influenza Vaccine (LAIV) Market Challenges
Table 22. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (K MT)
Table 23. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Type (M USD)
Table 24. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Type (2019-2024)
Table 25. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2019-2024)
Table 26. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) by Type (2019-2024)
Table 27. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Share by Type (2019-2024)
Table 28. Global Live Attenuated Influenza Vaccine (LAIV) Price (USD/MT) by Type (2019-2024)
Table 29. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Application
Table 30. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Application
Table 31. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2019-2024) & (K MT)
Table 32. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2019-2024)
Table 33. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2019-2024) & (M USD)
Table 34. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application (2019-2024)
Table 35. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2019-2024)
Table 36. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K MT)
Table 37. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2019-2024)
Table 38. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K MT)
Table 39. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K MT)
Table 40. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K MT)
Table 41. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K MT)
Table 42. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K MT)
Table 43. Global Live Attenuated Influenza Vaccine (LAIV) Production (K MT) by Region (2019-2024)
Table 44. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Region (2019-2024)
Table 45. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2019-2024)
Table 46. Global Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 47. North America Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 48. Europe Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 49. Japan Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 50. China Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 51. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 52. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 53. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 54. Sanofi Pasteur Business Overview
Table 55. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis
Table 56. Sanofi Pasteur Recent Developments
Table 57. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 58. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 59. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 60. AstraZeneca Business Overview
Table 61. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis
Table 62. AstraZeneca Recent Developments
Table 63. CSL Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 64. CSL Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 65. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 66. CSL Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis
Table 67. CSL Business Overview
Table 68. CSL Recent Developments
Table 69. Abbott Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 70. Abbott Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 71. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 72. Abbott Business Overview
Table 73. Abbott Recent Developments
Table 74. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 75. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 76. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 77. GlaxoSmithKline Business Overview
Table 78. GlaxoSmithKline Recent Developments
Table 79. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 80. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 81. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 82. Serum Institute Business Overview
Table 83. Serum Institute Recent Developments
Table 84. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 85. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 86. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 87. Fluenz Tetra Business Overview
Table 88. Fluenz Tetra Recent Developments
Table 89. Cytiva Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 90. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 91. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Cytiva Business Overview
Table 93. Cytiva Recent Developments
Table 94. BioDiem Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 95. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 96. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. BioDiem Business Overview
Table 98. BioDiem Recent Developments
Table 99. FluMist Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 100. FluMist Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 101. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. FluMist Business Overview
Table 103. FluMist Recent Developments
Table 104. GSK Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 105. GSK Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 106. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 107. GSK Business Overview
Table 108. GSK Recent Developments
Table 109. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 110. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 111. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 112. ChangChun High and New Technology Business Overview
Table 113. ChangChun High and New Technology Recent Developments
Table 114. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 115. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 116. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 117. BCHT Biotechnology Business Overview
Table 118. BCHT Biotechnology Recent Developments
Table 119. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2025-2032) & (K MT)
Table 120. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region (2025-2032) & (M USD)
Table 121. North America Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2025-2032) & (K MT)
Table 122. North America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2025-2032) & (M USD)
Table 123. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2025-2032) & (K MT)
Table 124. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2025-2032) & (M USD)
Table 125. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2025-2032) & (K MT)
Table 126. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region (2025-2032) & (M USD)
Table 127. South America Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2025-2032) & (K MT)
Table 128. South America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2025-2032) & (M USD)
Table 129. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Consumption Forecast by Country (2025-2032) & (Units)
Table 130. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2025-2032) & (M USD)
Table 131. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Type (2025-2032) & (K MT)
Table 132. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Type (2025-2032) & (M USD)
Table 133. Global Live Attenuated Influenza Vaccine (LAIV) Price Forecast by Type (2025-2032) & (USD/MT)
Table 134. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) Forecast by Application (2025-2032)
Table 135. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Application (2025-2032) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Live Attenuated Influenza Vaccine (LAIV) Market Size Comparison by Region (M USD)
Table 5. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Manufacturers (2019-2024)
Table 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Influenza Vaccine (LAIV) as of 2022)
Table 10. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (USD/MT) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Live Attenuated Influenza Vaccine (LAIV) Sales Sites and Area Served
Table 12. Manufacturers Live Attenuated Influenza Vaccine (LAIV) Product Type
Table 13. Global Live Attenuated Influenza Vaccine (LAIV) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Live Attenuated Influenza Vaccine (LAIV)
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Live Attenuated Influenza Vaccine (LAIV) Market Challenges
Table 22. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (K MT)
Table 23. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Type (M USD)
Table 24. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Type (2019-2024)
Table 25. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2019-2024)
Table 26. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) by Type (2019-2024)
Table 27. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Share by Type (2019-2024)
Table 28. Global Live Attenuated Influenza Vaccine (LAIV) Price (USD/MT) by Type (2019-2024)
Table 29. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Application
Table 30. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Application
Table 31. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2019-2024) & (K MT)
Table 32. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2019-2024)
Table 33. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2019-2024) & (M USD)
Table 34. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application (2019-2024)
Table 35. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2019-2024)
Table 36. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K MT)
Table 37. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2019-2024)
Table 38. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K MT)
Table 39. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K MT)
Table 40. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K MT)
Table 41. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K MT)
Table 42. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K MT)
Table 43. Global Live Attenuated Influenza Vaccine (LAIV) Production (K MT) by Region (2019-2024)
Table 44. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Region (2019-2024)
Table 45. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2019-2024)
Table 46. Global Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 47. North America Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 48. Europe Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 49. Japan Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 50. China Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 51. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 52. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 53. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 54. Sanofi Pasteur Business Overview
Table 55. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis
Table 56. Sanofi Pasteur Recent Developments
Table 57. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 58. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 59. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 60. AstraZeneca Business Overview
Table 61. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis
Table 62. AstraZeneca Recent Developments
Table 63. CSL Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 64. CSL Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 65. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 66. CSL Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis
Table 67. CSL Business Overview
Table 68. CSL Recent Developments
Table 69. Abbott Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 70. Abbott Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 71. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 72. Abbott Business Overview
Table 73. Abbott Recent Developments
Table 74. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 75. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 76. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 77. GlaxoSmithKline Business Overview
Table 78. GlaxoSmithKline Recent Developments
Table 79. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 80. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 81. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 82. Serum Institute Business Overview
Table 83. Serum Institute Recent Developments
Table 84. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 85. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 86. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 87. Fluenz Tetra Business Overview
Table 88. Fluenz Tetra Recent Developments
Table 89. Cytiva Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 90. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 91. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Cytiva Business Overview
Table 93. Cytiva Recent Developments
Table 94. BioDiem Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 95. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 96. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. BioDiem Business Overview
Table 98. BioDiem Recent Developments
Table 99. FluMist Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 100. FluMist Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 101. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. FluMist Business Overview
Table 103. FluMist Recent Developments
Table 104. GSK Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 105. GSK Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 106. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 107. GSK Business Overview
Table 108. GSK Recent Developments
Table 109. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 110. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 111. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 112. ChangChun High and New Technology Business Overview
Table 113. ChangChun High and New Technology Recent Developments
Table 114. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 115. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 116. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 117. BCHT Biotechnology Business Overview
Table 118. BCHT Biotechnology Recent Developments
Table 119. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2025-2032) & (K MT)
Table 120. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region (2025-2032) & (M USD)
Table 121. North America Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2025-2032) & (K MT)
Table 122. North America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2025-2032) & (M USD)
Table 123. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2025-2032) & (K MT)
Table 124. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2025-2032) & (M USD)
Table 125. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2025-2032) & (K MT)
Table 126. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region (2025-2032) & (M USD)
Table 127. South America Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2025-2032) & (K MT)
Table 128. South America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2025-2032) & (M USD)
Table 129. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Consumption Forecast by Country (2025-2032) & (Units)
Table 130. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2025-2032) & (M USD)
Table 131. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Type (2025-2032) & (K MT)
Table 132. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Type (2025-2032) & (M USD)
Table 133. Global Live Attenuated Influenza Vaccine (LAIV) Price Forecast by Type (2025-2032) & (USD/MT)
Table 134. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) Forecast by Application (2025-2032)
Table 135. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Application (2025-2032) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Live Attenuated Influenza Vaccine (LAIV)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD), 2019-2032
Figure 5. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) (2019-2032)
Figure 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (M USD)
Figure 11. Live Attenuated Influenza Vaccine (LAIV) Sales Share by Manufacturers in 2023
Figure 12. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers in 2023
Figure 13. Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Live Attenuated Influenza Vaccine (LAIV) Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Type
Figure 18. Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2019-2024)
Figure 19. Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type in 2023
Figure 20. Market Size Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2019-2024)
Figure 21. Market Size Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application
Figure 24. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2019-2024)
Figure 25. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application in 2023
Figure 26. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application (2019-2024)
Figure 27. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application in 2023
Figure 28. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2019-2024)
Figure 29. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2019-2024)
Figure 30. North America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 31. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2023
Figure 32. U.S. Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 33. Canada Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) and Growth Rate (2019-2024)
Figure 34. Mexico Live Attenuated Influenza Vaccine (LAIV) Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 36. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2023
Figure 37. Germany Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 38. France Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 39. U.K. Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 40. Italy Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 41. Russia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 42. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2023
Figure 44. China Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 45. Japan Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 46. South Korea Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 47. India Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 48. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 49. South America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)
Figure 50. South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2023
Figure 51. Brazil Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 52. Argentina Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 53. Columbia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 54. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 57. UAE Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 58. Egypt Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 59. Nigeria Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 60. South Africa Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 61. Global Live Attenuated Influenza Vaccine (LAIV) Production Market Share by Region (2019-2024)
Figure 62. North America Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2019-2024)
Figure 63. Europe Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2019-2024)
Figure 64. Japan Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2019-2024)
Figure 65. China Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2019-2024)
Figure 66. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Live Attenuated Influenza Vaccine (LAIV) Market Share Forecast by Type (2025-2032)
Figure 70. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Application (2025-2032)
Figure 71. Global Live Attenuated Influenza Vaccine (LAIV) Market Share Forecast by Application (2025-2032)
Figure 1. Product Picture of Live Attenuated Influenza Vaccine (LAIV)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD), 2019-2032
Figure 5. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) (2019-2032)
Figure 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (M USD)
Figure 11. Live Attenuated Influenza Vaccine (LAIV) Sales Share by Manufacturers in 2023
Figure 12. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers in 2023
Figure 13. Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Live Attenuated Influenza Vaccine (LAIV) Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Type
Figure 18. Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2019-2024)
Figure 19. Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type in 2023
Figure 20. Market Size Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2019-2024)
Figure 21. Market Size Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application
Figure 24. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2019-2024)
Figure 25. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application in 2023
Figure 26. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application (2019-2024)
Figure 27. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application in 2023
Figure 28. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2019-2024)
Figure 29. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2019-2024)
Figure 30. North America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 31. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2023
Figure 32. U.S. Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 33. Canada Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) and Growth Rate (2019-2024)
Figure 34. Mexico Live Attenuated Influenza Vaccine (LAIV) Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 36. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2023
Figure 37. Germany Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 38. France Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 39. U.K. Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 40. Italy Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 41. Russia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 42. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2023
Figure 44. China Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 45. Japan Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 46. South Korea Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 47. India Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 48. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 49. South America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)
Figure 50. South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2023
Figure 51. Brazil Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 52. Argentina Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 53. Columbia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 54. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 57. UAE Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 58. Egypt Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 59. Nigeria Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 60. South Africa Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)
Figure 61. Global Live Attenuated Influenza Vaccine (LAIV) Production Market Share by Region (2019-2024)
Figure 62. North America Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2019-2024)
Figure 63. Europe Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2019-2024)
Figure 64. Japan Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2019-2024)
Figure 65. China Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2019-2024)
Figure 66. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Live Attenuated Influenza Vaccine (LAIV) Market Share Forecast by Type (2025-2032)
Figure 70. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Application (2025-2032)
Figure 71. Global Live Attenuated Influenza Vaccine (LAIV) Market Share Forecast by Application (2025-2032)
